Molecular Instruments® (MI), the inventor of the HCR™ platform, today announced key enhancements to its HCR™ Gold and HCR™ Pro product lines. These upgrades include next-generation chemistry for ...

Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins. The profit surge in Q2 2025 included a ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

Revenue declined sharply to $8.7 million in Q2 fiscal year 2025, missing analyst expectations by 34.1% and falling 55.8% compared to the prior year period. Net loss widened to $50.5 million for Q2 ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis "AbbVie delivered another outstanding quarter with strong ...

A WEHI-led study reveals that blocking minor splicing – an RNA process critical for cell division – reduces tumour growth in ...

Researchers have found in ALPACA trial that Lepodisiran demonstrated a substantial reduction in lipoprotein(a) levels, ...

In a statement, the Cambridge, Massachusetts-based company said that shipments of Elevidys (delandistrogene moxeparvovec) will restart while it continues dialogue with the FDA "on next steps in the ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...